Journal of Dental Rehabilitation and Applied Science (구강회복응용과학지)

Korean Academy of Stomatognathic Function and Occlusion (대한턱관절교합학회)
권호 표지

Muscle Weakness after Repeated Injection of Botulinum Toxin Type A Evaluated by Dental Prescale

덴탈 프리스케일로 평가한 보툴리눔 A형 독소 반복 주사 후 근육의 약화

  • Byun, Young-Sub (Department of Oral medicine, college of dentistry, Yonsei University) ;
  • Song, Ji-Hee (Department of Oral medicine, college of dentistry, Yonsei University) ;
  • Choi, Young-Chan (Department of Oral medicine, college of dentistry, Yonsei University) ;
  • Kim, Seong-Taek (Department of Oral medicine, college of dentistry, Yonsei University)
  • 변영섭 (연세대학교 치과대학 구강내과학교실) ;
  • 송지희 (연세대학교 치과대학 구강내과학교실) ;
  • 최영찬 (연세대학교 치과대학 구강내과학교실) ;
  • 김성택 (연세대학교 치과대학 구강내과학교실)
  • Received : 2010.02.05
  • Accepted : 2010.03.25
  • Published : 2010.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Botulinum toxin type A(BTX-A) has been applied successfully to treat masseteric hypertrophy. However it can cause muscle weakness. This study was designed to measure the change in maximum bite force(MBF) after BTX-A injection into human masseter muscle and to evaluate the influence of a booster(repeated) injection. Thirty volunteers completed 18-week follow-up and MBF was measured. At 18 weeks after the first injection, a booster injection was given to 14 patients and they were followed up until 18 weeks from the booster injection. The mean MBF was approximately 20% lower at 2 weeks than before the injection, and it recovered gradually after 4 weeks to return to the preinjection level at 12 weeks. The MBF differed significantly between before the injection and at 2, 4, and 8 weeks after the injection(p<0.05). In booster injection group(n=14),the MBF decreased markedly at 6 weeks(p<0.05),and it recovered gradually in 12 weeks. The MBF was significantly reduced after booster injection of BTX-A into the human masseter muscle. The degree of discomfort experienced by the subjects had little effect on normal mastication.

A형 보툴리눔 독소(botulinum toxin type A, BTX-A)는 교근 비대의 치료에 성공적으로 적용되어 왔지만 주사 부위 근육의 약화를 초래한다. 이 연구는 BTX-A를 사람 교근에 주사한 후 최대 교합력(Maximum Bite Force, MBF) 의 변화를 측정하고, 반복 주사의 효과를 평가하기 위해 시행되었다. 30명의 자원자들을 18주간 추적 관찰하고, 최대 교합력을 측정하였다. 1차 주사로부터 18주가 경과한 후 시술에 만족한 16명은 제외하고 나머지 14명에게 반복 주사를 시행하였고, 다시 18주간 측정하였다. 평균 최대 교합력은 주사 2주 후 20% 감소하였다가 4주부터 점차 회복되었으며, 12주 뒤에는 주사 이전 수준으로 회복되었다. 최대 교합력은 주사 전과 주사 2주, 4주, 8주 후에서 유의한 차이를 보였다(p<.05). 반복 주사군(n=14)의 최대 교합력은 6주에 두드러진 감소를 보였다가(p<.05) 12주간 점차 회복되었다. 실험군이 경험한 불편감의 수준은 일반적인 저작에는 거의 영향을 미치지 않았다.

Keywords

References

  1. Jankovic, J., Brin, M. F. Therapeutic uses of botulinum toxin. NEnglJMed 1991;324:1186-1194. https://doi.org/10.1056/NEJM199104253241707
  2. Simpson, L. L. Botulinum toxin: a deadly poison sheds its negative image. AnnInternMed 1996;125:616-617. https://doi.org/10.7326/0003-4819-125-7-199610010-00013
  3. Carruthers, J. D., Carruthers, J. A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. JDermatolSurgOncol 1992;18:17-21. https://doi.org/10.1111/j.1524-4725.1992.tb03295.x
  4. Blitzer, A., Brin, M. F., Keen, M. S., et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. ArchOtolaryngolHeadNeckSurg 1993;119:1018-1022. https://doi.org/10.1001/archotol.1993.01880210108015
  5. Carruthers, J. A., Lowe, N. J., Menter, M. A., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. JAmAcadDermatol 2002;46:840-849. https://doi.org/10.1067/mjd.2002.121356
  6. Blitzer, A., Binder, W. J., Aviv, J. E., et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. ArchOtolaryngolHeadNeckSurg 1997;123:389-392. https://doi.org/10.1001/archoto.123.4.389
  7. Clark, G. T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. PhysMedRehabilClinNAm 2003;14:727-748. https://doi.org/10.1016/S1047-9651(03)00044-5
  8. Moore, A. P., Wood, G. D. The medical management of masseteric hypertrophy with botulinum toxin type A. BrJOralMaxillofacSurg 1994;32:26-28. https://doi.org/10.1016/0266-4356(94)90168-6
  9. To, E. W., Ahuja, A. T., Ho, W. S., et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. BrJPlastSurg 2001;54:197-200.
  10. Choe, S. W., Cho, W. I., Lee, C. K., et al. Effects of botulinum toxin type A on contouring of the lower face. 2005;31:502-507;discussion507. https://doi.org/10.1097/00042728-200505000-00002
  11. Kim, N. H., Chung, J. H., Park, R. H., et al. The use of botulinum toxin type A in aesthetic mandibular contouring. PlastReconstrSurg 2005;115:919-930. https://doi.org/10.1097/01.PRS.0000153236.79775.A0
  12. Kim, H. J., Yum, K. W., Lee, S. S., et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. 2003;29:484-489. https://doi.org/10.1046/j.1524-4725.2003.29117.x
  13. Park, M. Y., Ahn, K. Y., Jung, D. S. Botulinum toxin type A treatment for contouring of the lower face. 2003;29:477-483. https://doi.org/10.1046/j.1524-4725.2003.29116.x
  14. Kim, J. H., Shin, J. H., Kim, S. T., et al. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurementsted tuman masseter muscle. PlastReconstrSurg 2007;119:711-717. https://doi.org/10.1097/01.prs.0000239453.67423.99
  15. Yu, C. C., Chen, P. K., Chen, Y. R. Botulinum toxin a for lower facial contouring: a prospective study. AestheticPlastSurg 2007;31:445-451;discussion452. https://doi.org/10.1007/s00266-007-0081-8
  16. Alam, M., Dover, J. S., Klein, A. W., et al. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject. ArchDermatol 2002;138:1180-1185. https://doi.org/10.1001/archderm.138.9.1180
  17. Ahn, K. Y., Kim, S. T. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. PlastReconstrSurg 2007;120:1662-1666. https://doi.org/10.1097/01.prs.0000282309.94147.22
  18. Borodic, G. E., Ferrante, R., Pearce, L. B., et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. MovDisord 9:31-39,1994. https://doi.org/10.1002/mds.870090106
  19. Borodic, G. E., Ferrante, R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. JClinNeuroophthalmol 1992;12:121-127. https://doi.org/10.3109/01658109209058127
  20. Rzany B,Dill-Muller D,Grablowitz D,Heckmann M,Caird D;German-Austrian Retrospective Study Group. Repeated botulinumtoxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. 2007;33:S18-25. https://doi.org/10.1111/j.1524-4725.2006.32327.x
  21. Oshima, M., Middlebrook, J. L., Atassi, M. Z. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. ImmunolLett 1998;60:7-12. https://doi.org/10.1016/S0165-2478(97)00124-7